Bright Minds Biosciences Pty Ltd

Quick facts

Phase 2 pipeline

• BMB-101 · Immunology
  BMB-101 is a small molecule that targets the S1P1 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Bright Minds Biosciences Pty Ltd portfolio CI brief
• Bright Minds Biosciences Pty Ltd pipeline updates RSS